SEC Form 4 · accession 0001209191-15-000384
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ron Bentsur
Officer — Chief Executive Officer · Director
Period of report
Dec 30, 2014
Accepted (ET)
Jan 2, 2015 · 9:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 30, 2014 | S | 200,000 | $14.11 | D | 717,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects the weighted average sale price. The range of prices for such transaction is $14.00 to $14.29.
- F2Includes 26,070 shares of restricted stock. In addition, Mr. Bentsur holds stock options to purchase up to 1,002,932 shares of Keryx common stock.